What do we know about Rimonabant (Acomplia)?
Rimonabant (also known as Zimulti, Acomplia or Slimona) is an anorectic anti obesity drug. It is a CB1 cannabinoid receptor antagonist. Rimonabant has been found to stop food craving enough to help people lose weight, and could also help curb other unhealthy urges, such as smoking. This is a non-control weightloss solution that in one study, helped people who were overweight drop an average of 20 pounds, and was found to be very useful for patients who suffer from obesity. How does Rimonabant (Acomplia) work? • Rimonabant acts by selectively blocking CB1 receptors found in the brain and in peripheral organs important in glucose and lipid (or fat) metabolism, including adipose tissue, the liver, gastrointestinal tract and muscle1 • Rimonabant switches off the same brain circuits that make people hungry when they smoke cannabis • CB1 receptor blockade with Rimonabant acts to decrease the overactivity of the endocannabinoid system (EC system)2,3. The EC system is a recently characterised
